Relay Therapeutics, Inc. (RLAY) has a negative trailing P/E of -8.9, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -11.22%.
Criteria proven by this page:
Overall SharesGrow Score: 52/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2018 | -1.8 | 0.00 | -0.79 | 0.00 | - |
| 2019 | -2.3 | 0.11 | -0.83 | 0.00 | - |
| 2020 | -71.4 | 0.86 | 4.90 | 45.28 | - |
| 2021 | -8.0 | -0.16 | 3.25 | 964.56 | - |
| 2022 | -5.8 | 0.18 | 1.76 | 1,214.17 | - |
| 2023 | -3.9 | -0.51 | 1.79 | 52.83 | - |
| 2024 | -1.7 | 0.11 | 0.76 | 58.82 | - |
| 2025 | -5.3 | 0.17 | 2.56 | 94.54 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2018 | $-19.63 | $0.00 | $-48.79M | - |
| 2019 | $-15.53 | $0.00 | $-66.5M | - |
| 2020 | $-1.15 | $82.65M | $-49.01M | -59.3% |
| 2021 | $-5.22 | $3.03M | $-496.81M | -16401.7% |
| 2022 | $-2.27 | $1.38M | $-254.26M | -18411.2% |
| 2023 | $-2.79 | $25.55M | $-341.97M | -1338.7% |
| 2024 | $-2.36 | $10.01M | $-337.71M | -3374.7% |
| 2025 | $-1.61 | $15.36M | $-276.48M | -1800.6% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.53 | $-1.86 – $-1.31 | $5.84M | $742.53K – $11.21M | 8 |
| 2027 | $-1.48 | $-1.66 – $-1.24 | $21.93M | $11.76M – $32.1M | 5 |
| 2028 | $-1.42 | $-2.20 – $-1.05 | $27.36M | $10.69M – $44.48M | 5 |
| 2029 | $-1.15 | $-2.08 – $-0.24 | $112.4M | $43.93M – $182.72M | 1 |
| 2030 | $-0.43 | $-0.78 – $-0.09 | $340.04M | $132.9M – $552.78M | 1 |
